

David Siegel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11315312/publications.pdf>

Version: 2024-02-01

35
papers

12,638
citations

249298

26
h-index

425179

34
g-index

35
all docs

35
docs citations

35
times ranked

10416
citing authors

#	ARTICLE	IF	CITATIONS
1	Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. <i>New England Journal of Medicine</i> , 2021, 384, 705-716.	13.9	1,129
2	Selinexor for the treatment of patients with previously treated multiple myeloma. <i>Expert Review of Hematology</i> , 2021, 14, 697-706.	1.0	6
3	Efficacy and safety of carfilzomib-based regimens in frail patients with relapsed and/or refractory multiple myeloma. <i>Blood Advances</i> , 2020, 4, 5449-5459.	2.5	17
4	A Phase Ib/II Study of Oprozomib in Patients with Advanced Multiple Myeloma and Waldenström Macroglobulinemia. <i>Clinical Cancer Research</i> , 2019, 25, 4907-4916.	3.2	36
5	Weekly carfilzomib, lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: A phase 1b study. <i>American Journal of Hematology</i> , 2019, 94, 794-802.	2.0	10
6	Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma. <i>New England Journal of Medicine</i> , 2019, 380, 1726-1737.	13.9	1,130
7	Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure: a subgroup analysis of ENDEAVOR. <i>Blood</i> , 2019, 133, 147-155.	0.6	33
8	Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2018, 36, 859-866.	0.8	140
9	Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenström macroglobulinemia. <i>Blood</i> , 2018, 131, 855-863.	0.6	105
10	Safety and tolerability of pomalidomide-based regimens (pomalidomide-carfilzomib-dexamethasone with Tj ETQq0 0 0 rgBT /Overl a case series. <i>Hematological Oncology</i> , 2017, 35, 246-251.	0.8	5
11	Optimal treatment strategies in myeloma: An argument against maintenance therapy after autologous stem cell transplantation. <i>Seminars in Oncology</i> , 2016, 43, 714-717.	0.8	1
12	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia. , 2016, 4, 90.		17
13	Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. <i>Blood</i> , 2016, 127, 2955-2962.	0.6	686
14	Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma. <i>Blood</i> , 2016, 128, 1174-1180.	0.6	110
15	Clinical activity of carfilzomib correlates with inhibition of multiple proteasome subunits: application of a novel pharmacodynamic assay. <i>British Journal of Haematology</i> , 2016, 173, 884-895.	1.2	29
16	Real-world treatment patterns and associated progression-free survival in relapsed/refractory multiple myeloma among US community oncology practices. <i>Expert Review of Hematology</i> , 2016, 9, 707-717.	1.0	37
17	Relationship Between Carfilzomib Dose and Efficacy Outcomes in Patients With Relapsed and/or Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 680-686.	0.2	6
18	The role of histone deacetylase inhibitors in patients with relapsed/refractory multiple myeloma. <i>Leukemia and Lymphoma</i> , 2014, 55, 11-18.	0.6	4

#	ARTICLE	IF	CITATIONS
19	Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies. <i>Haematologica</i> , 2013, 98, 1753-1761.	1.7	300
20	Phase I, multicentre, dose-escalation trial of monotherapy with milatuzumab (humanized) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 707 T Journal of Haematology, 2013, 163, 478-486.	1.2	89
21	Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib. <i>Blood</i> , 2013, 121, 1961-1967.	0.6	152
22	Phase Ib Study of Panobinostat and Bortezomib in Relapsed or Relapsed and Refractory Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2013, 31, 3696-3703.	0.8	123
23	Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study. <i>Leukemia</i> , 2012, 26, 149-157.	3.3	664
24	Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma. <i>Leukemia and Lymphoma</i> , 2012, 53, 1820-1823.	0.6	109
25	Effects of Lenalidomide and Dexamethasone Treatment Duration on Survival in Patients With Relapsed or Refractory Multiple Myeloma Treated With Lenalidomide and Dexamethasone. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 38-43.	0.2	59
26	Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. <i>Blood</i> , 2011, 117, 4691-4695.	0.6	849
27	Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma. <i>British Journal of Haematology</i> , 2009, 146, 164-170.	1.2	79
28	First thalidomide clinical trial in multiple myeloma: a decade. <i>Blood</i> , 2008, 112, 1035-1038.	0.6	47
29	Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America. <i>New England Journal of Medicine</i> , 2007, 357, 2133-2142.	13.9	1,186
30	Long-term outcome results of the first tandem autotransplant trial for multiple myeloma. <i>British Journal of Haematology</i> , 2006, 135, 158-164.	1.2	155
31	A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma. <i>New England Journal of Medicine</i> , 2003, 348, 2609-2617.	13.9	2,460
32	Myeloma of the central nervous system: association with high-risk chromosomal abnormalities, plasmablastic morphology and extramedullary manifestations. <i>British Journal of Haematology</i> , 2002, 117, 103-108.	1.2	133
33	Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. <i>Blood</i> , 2000, 95, 4008-4010.	0.6	290
34	Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. <i>Blood</i> , 2000, 95, 4008-4010.	0.6	9
35	Antitumor Activity of Thalidomide in Refractory Multiple Myeloma. <i>New England Journal of Medicine</i> , 1999, 341, 1565-1571.	13.9	2,433